- European Medicines Agency Recommends Granting a Conditional Marketing Authorisation for Cabozantinib for the Treatment of Medullary Thyroid Cancer
- Obinutuzumab/Chlorambucil in the First-Line Treatment of Older CLL Patients
- Phase III Study of Idelalisib and Rituximab for Previously Treated Patients with Chronic Lymphocytic Leukaemia
- Learning From the FDA Breakthrough Therapies Pathway
- Onartuzumab in Combination with Erlotinib in Patients with Advanced NSCLC
- European Medicines Agency Recommends Changes in Use of Ponatinib in Order to Minimise Risk of Thrombosis
- European Medicines Agency Recommends Extension of Indications for Paclitaxel Protein-bound Particles for Injectable Suspension (Albumin-bound)
- European Medicines Agency Recommends Refusal of the Marketing Authorisation for Masitinib
- European Medicines Agency Recommends Change in Indication for Cetuximab to RAS Wild-type Metastatic Colorectal Cancer
- No Survival Benefit from Adding Cetuximab to Chemoradiotherapy in Patients with Stage III Non-Small Cell Lung Cancer
- European Medicines Agency Issues Opinion that the Benefits of Deonosumab Do Not Outweigh its Risks in Patients with Castration-Resistant Prostate Cancer at High Risk of Spreading to the Bones
- European Medicines Agency Warning on Risk of Arterial Thrombosis with Ponatinib
- Hitting Angiogenesis in Gastric Cancer
- ECC 2013 Press Release: Biological Therapy with Cediranib Improves Survival in Women with Recurrent Ovarian Cancer
- ECC 2013 Press Release: New Trial Combining Anti-Cancer Drug and Radiotherapy may Result in a new Treatment for the most Aggressive Brain Tumour
- ESMO @ ECC 2013: A Phase III Study of Tivantinib Plus Erlotinib Did Not Meet a Primary Endpoint in Patients with Locally-advanced or Metastatic, Non-squamous NSCLC
- ESMO @ ECC 2013: Similar Phase III Results Reported for Dovitinib vs. Sorafenib Treatment in Patients with Metastatic Renal Cell Carcinoma
- ECC 2013 Press Release: Everolimus Slows Disease Progression in Advanced Papillary Kidney Cancer Patients
- ESMO @ ECC 2013: Vemurafenib in Patients With RAI Refractory, Progressive, BRAFV600E-mutated Papillary Thyroid Cancer
- ESMO @ ECC 2013: Phase III FIRE-3 Trial Data Show Most Patients with Wild-Type RAS Metastatic Colorectal Cancer Benefit from First-Line FOLFIRI Plus Cetuximab Treatment
- ECC 2013 Press Release: Anti-Cancer Drug T-DM1 Benefits Women with Avanced Breast Cancer who have Failed Several Previous Treatments: Results from TH3RESA Trial
- European Medicines Agency Recommends a Variation to the Terms of the Marketing Authorisation for Everolimus
- European Medicines Agency Recommends to Extend the Indications for Ipilimumab
- European Medicines Agency Recommends Granting a Marketing Authorisation for Radium-223 Chloride
- European Medicines Agency Recommends Granting a Marketing Authorisation for Trastuzumab Emtansine